BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

...of Zika infection and dengue fever caused by serotypes DENV1-4. Massachusetts Institute of Technology ; Mount Sinai School of Medicine...
BioCentury | Feb 12, 2015
Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 2 group F member 1 (NR2F1; COUP-TFI)

...M.S. et al. Nat. Commun.; published online Jan. 30, 2015 doi:10.1038/ncomms7170 CONTACT: Julio A. Aguirre-Ghiso, Mount Sinai School of Medicine...
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); EGFR2 (HER2; ErbB2; neu)

...al. Proc. Natl. Acad. Sci. USA; published online Dec. 2, 2014 doi:10.1073/pnas.1421422111 CONTACT: Mone Zaidi, Mount Sinai School of Medicine...
...al. Proc. Natl. Acad. Sci. USA; published online Dec. 2, 2014 doi:10.1073/pnas.1421410111 CONTACT: Mone Zaidi, Mount Sinai School of Medicine...
BioCentury | Mar 20, 2014
Distillery Therapeutics

Indication: Renal disease

...Azeloglu, E.U. et al. Sci. Signal.; published online Feb. 4, 2014; doi:10.1126/scisignal.2004621 Contact: Ravi Iyengar, Mount Sinai School of Medicine...
BioCentury | Jun 3, 2013
Regulation

Suvorexant safety

...the low and high doses of suvorexant separately." Emilia Bagiella, a professor of biostatistics at Mount Sinai School of Medicine...
...University School of Medicine , Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Mount Sinai School of Medicine...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Neurology

...al. Proc. Natl. Acad. Sci. USA; published online April 29, 2013; doi:10.1073/pnas.1214696110 Contact: Venetia Zachariou, Mount Sinai School of Medicine...
BioCentury | Jan 17, 2013
Distillery Techniques

Technology: Drug platforms

...unavailable Chaudhury, D. et al. Nature; published online Dec. 12, 2012; doi:10.1038/nature11713 Contact: Ming-Hu Han, Mount Sinai School of Medicine...
BioCentury | Dec 20, 2012
Distillery Therapeutics

Indication: Neurology

...Fuchs, T. et al. Nat. Genet.; published online Dec. 9, 2012; doi:10.1038/ng.2496 Contact: Laurie Ozelius, Mount Sinai School of Medicine...
BioCentury | Dec 20, 2012
Strategy

MRC Technology extends reach

...this year, MRC Technology announced a partnership to apply MRC Technology's antibody humanization capabilities to Mount Sinai School of Medicine...
...London, U.K. Chinese Academy of Sciences , Beijing, China Medical Research Council , London, U.K. Mount Sinai School of Medicine...
...Technology's Centre for Therapeutic Discovery Small molecules 2012 Infectious disease, drug addiction and autoimmune disease Mount Sinai School of Medicine...
BioCentury | Nov 12, 2012
Company News

GNS Healthcare, Dana-Farber Cancer Institute, Mount Sinai School of Medicine deal

...treatments for patients. GNS Healthcare Inc. , Cambridge, Mass. Dana-Farber Cancer Institute , Boston, Mass. Mount Sinai School of Medicine...
Items per page:
1 - 10 of 146
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

...of Zika infection and dengue fever caused by serotypes DENV1-4. Massachusetts Institute of Technology ; Mount Sinai School of Medicine...
BioCentury | Feb 12, 2015
Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 2 group F member 1 (NR2F1; COUP-TFI)

...M.S. et al. Nat. Commun.; published online Jan. 30, 2015 doi:10.1038/ncomms7170 CONTACT: Julio A. Aguirre-Ghiso, Mount Sinai School of Medicine...
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); EGFR2 (HER2; ErbB2; neu)

...al. Proc. Natl. Acad. Sci. USA; published online Dec. 2, 2014 doi:10.1073/pnas.1421422111 CONTACT: Mone Zaidi, Mount Sinai School of Medicine...
...al. Proc. Natl. Acad. Sci. USA; published online Dec. 2, 2014 doi:10.1073/pnas.1421410111 CONTACT: Mone Zaidi, Mount Sinai School of Medicine...
BioCentury | Mar 20, 2014
Distillery Therapeutics

Indication: Renal disease

...Azeloglu, E.U. et al. Sci. Signal.; published online Feb. 4, 2014; doi:10.1126/scisignal.2004621 Contact: Ravi Iyengar, Mount Sinai School of Medicine...
BioCentury | Jun 3, 2013
Regulation

Suvorexant safety

...the low and high doses of suvorexant separately." Emilia Bagiella, a professor of biostatistics at Mount Sinai School of Medicine...
...University School of Medicine , Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Mount Sinai School of Medicine...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Neurology

...al. Proc. Natl. Acad. Sci. USA; published online April 29, 2013; doi:10.1073/pnas.1214696110 Contact: Venetia Zachariou, Mount Sinai School of Medicine...
BioCentury | Jan 17, 2013
Distillery Techniques

Technology: Drug platforms

...unavailable Chaudhury, D. et al. Nature; published online Dec. 12, 2012; doi:10.1038/nature11713 Contact: Ming-Hu Han, Mount Sinai School of Medicine...
BioCentury | Dec 20, 2012
Distillery Therapeutics

Indication: Neurology

...Fuchs, T. et al. Nat. Genet.; published online Dec. 9, 2012; doi:10.1038/ng.2496 Contact: Laurie Ozelius, Mount Sinai School of Medicine...
BioCentury | Dec 20, 2012
Strategy

MRC Technology extends reach

...this year, MRC Technology announced a partnership to apply MRC Technology's antibody humanization capabilities to Mount Sinai School of Medicine...
...London, U.K. Chinese Academy of Sciences , Beijing, China Medical Research Council , London, U.K. Mount Sinai School of Medicine...
...Technology's Centre for Therapeutic Discovery Small molecules 2012 Infectious disease, drug addiction and autoimmune disease Mount Sinai School of Medicine...
BioCentury | Nov 12, 2012
Company News

GNS Healthcare, Dana-Farber Cancer Institute, Mount Sinai School of Medicine deal

...treatments for patients. GNS Healthcare Inc. , Cambridge, Mass. Dana-Farber Cancer Institute , Boston, Mass. Mount Sinai School of Medicine...
Items per page:
1 - 10 of 146